Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.
PIP is broken down into two parts with daily living starting at £73.90 for the lower rate, rising to £110.40 for higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback